EGFR and cancer: Literature data for different types of polymer nanoscale carriers decorated with anti-EGFR nanobodies points to an improved delivery of the NPs and the cargo to the EGFR-overexpressing cancer cells through EGFR-mediated internalization, and to an enhanced therapeutic efficacy due to the antagonistic activity [92–97].